Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol in renal transplant recipients
NCT01332799Phase 4
Key facts
- Status
- Terminated
- Start
- Feb 2011
- Primary completion
- Aug 2018
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- allopurinol
- Conditions
- cardiovascular diseases (CVD)
01
Overview
Phase 4, randomised, double-blind trial in cardiovascular diseases (CVD) comparing Allopurinol with Placebo (2 arms). Primary endpoints: Cardiovascular Events at 3 years and Endothelial Function at 3 years. Started Feb 2011; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Allopurinol
Allopurinol administered orally daily.
Placebo
Placebo administered orally daily.
03
Who it enrols
Adult kidney transplant recipients with stable renal function for at least 1 year, excluding those with gout, allergy to allopurinol, or use of azathioprine.
04
Endpoints
Primary
Cardiovascular Events
Endothelial Function
Secondary
Arterial Stiffness
Beyond the preview
Go deeper on NCT01332799.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01332799.